imatinib mesylate
The drugmaker will seek regulatory approval for Scemblix in first-line Ph-positive CML and other precision drugs in the coming months.
Takeda Nets FDA Accelerated Approval for Frontline Iclusig, Chemo Combo in Certain ALL Patients
The FDA approved the drug combination for Philadelphia chromosome-positive acute lymphoblastic leukemia based on the Phase III PhALLCON trial.
Ascentage Pharma, Innovent Biologics Treat First ALL Patient in Phase III Olverembatinib Trial
The firms are comparing their TKI plus chemo to Novartis' Gleevec plus chemo in first-line Philadelphia chromosome-positive acute lymphoblastic leukemia.
Takeda to Discuss Positive Phase III Iclusig Data in Upfront ALL With Regulators
The trial pitted Iclusig against the TKI Gleevec as first-line treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia patients.
NCI researchers performed a multi-platform study to elucidate the factors that can contribute to a patient's better-than-expected response to a drug.
Mar 12, 2019